Previous 10 | Next 10 |
2024-04-11 10:25:50 ET Summary Among their more prominent programs, Moderna is developing a vaccine-based treatment for solid tumors. Moderna's personalized neoantigen vaccine, mRNA-4157, has shown promising results in clinical trials for melanoma, and some preliminary activity in...
2024-04-11 09:24:54 ET More on Moderna Moderna Continues To Build A Pipeline Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript) Moderna stock climbs 8% am...
2024-04-11 09:04:00 ET U.S. stock index futures on Thursday ate into a chunk of their losses after the latest producer inflation report came in cooler than expected. Here are some stocks to watch on Thursday: ... Read the full article on Seeking Alpha For further detail...
2024-04-09 12:37:57 ET Moderna Inc (NASDAQ: MRNA) popped as much as 10% on Tuesday after a Jefferies analyst made upbeat remarks on new data for its experimental vaccine for head and neck cancer. MRNA-4157 has potential beyond melanoma The biotech giant reported positive early-s...
2024-04-09 11:26:54 ET More on Moderna Moderna Continues To Build A Pipeline Lukewarm Reaction To Moderna's Vaccine Day Sums Up Fine Margins In Play Moderna, Inc. (MRNA) Barclays 26th Annual Global Healthcare Conference (Transcript) Arbutus Biopharma jumps af...
Moderna, Inc. (NASDAQ: MRNA) is one of today's top gainers. The company's shares have moved 8.43% on the day to $113.94. Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, c...
2024-04-05 14:35:10 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The healthcare industry has historically provided significant returns to investors, with a predicted CAGR of 12.71% until 2027. Although many successful and profitable companies experience...
2024-04-05 13:54:07 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips With the market off to a rather wobbly start to the second quarter of 2024, investors may be looking for the most undervalued biotech stocks to buy in April that can offer more bang for one...
2024-04-03 12:45:37 ET Summary Moderna had a challenging 2023 as demand for its COVID-19 vaccines declined, but it still expects reasonable revenue in 2024. The company has a strong pipeline of products, including respiratory vaccines and potential joint flu/COVID-19 vaccines. ...
2024-04-03 12:27:33 ET More on Arbutus Biopharma Arbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call Transcript Arbutus Biopharma GAAP EPS of -$0.44 beats by $0.01, revenue of $18.1M misses by $3.04M Arbutus Biopharma gains after Markman hearing on Thursday in...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...